Form 4 for ARQT Arcutis Biotherapeutics, Inc.
Accepted 2025-11-17 00:00:00 ET · period of report 2025-11-13 · accession 0001866171-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-11-17 | 2025-11-13 | ARQT | Krishnamohan Neha | Dir | S - Sale+OE | $23.20 | -40.5K | 23.4K | -63% | -$939.5K |
| DM | 2025-11-17 | 2025-11-13 | ARQT | Krishnamohan Neha | Dir | M - OptEx | $8.28 | +39.3K | 50.4K | +353% | +$325.2K |
| DM | 2025-11-17 | 2025-11-13 | ARQT | Krishnamohan Neha | Dir | M - OptEx | $0.00 | -39.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-13 | S | D | 1,232 | $23.37 | 22,123 | D | — | — | |
| 2 | Common | Common Stock | 2025-11-13 | S | D | 39,272 | $23.19 | 23,355 | D | — | — | (F2) The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $22.86 to $23.60, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2025-11-13 | M | A | 12,220 | $7.51 | 62,627 | D | — | — | |
| 4 | Common | Common Stock | 2025-11-13 | M | A | 27,052 | $8.63 | 50,407 | D | — | — | |
| 5 | Derivative | Stock Option (right to buy) | 2025-11-13 | M | D | 27,052 | $0.00 | 0 | D | $8.63 · — to 2034-06-14 | 27,052 Common Stock | (F3) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. |
| 6 | Derivative | Stock Option (right to buy) | 2025-11-13 | M | D | 12,220 | $0.00 | 0 | D | $7.51 · — to 2033-05-31 | 12,220 Common Stock | (F4) The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. |